Gladstone NOW: The Campaign Join Us on the Journey ✕
241 - 255 of 429 Results Clear All
San Francisco Chronicle—Senior Investigator Warner Greene, MD, PhD, endorses presidential candidate Joe Biden's plan to fight the coronavirus pandemic, calling the plan “rational.”
Gladstone Experts COVID-19 Center for HIV Cure Research Greene Lab
San Francisco Chronicle—Some of the treatments the president received for COVID-19 were developed using cells derived from human embryonic tissue. In addition, many of the COVID-19 vaccine candidates were developed using fetal cell lines. Gladstone Senior Investigator Warner Greene explains how valuable fetal tissue research has been to research on cancer, HIV, spinal cord injuries, and many other diseases. He also describes how the president’s 2019 decision to cut federal funding for fetal cell research has damaged that progress.
Gladstone Experts COVID-19 Infectious Disease Greene Lab
abc News—In 2019, the Trump administration suspended federal funding for research involving fetal tissue. Gladstone President Deepak Srivastava explains that if the funding ban had been in place over the last few decades, many important drugs—including treatments for COVID-19—would not have been developed.
Gladstone Experts COVID-19 Roddenberry Stem Cell Center Srivastava Lab Stem Cells/iPSCs
Science is Fun!—Director of the Gladstone Institute of Virology Melanie Ott describes her latest work developing a CRISPR-based test for COVID-19, and the prospect for broadly acting antiviral therapeutics.
Gladstone Experts COVID-19 Infectious Disease Ott Lab
abc News—Gladstone President Deepak Srivastava, MD, comments on the fact that the experimental treatments President Trump received for COVID-19 were tested on cells that were derived from fetal tissue decades ago, and expresses concern that the Trump administration's current ban on the use of fetal tissue for research could slow efforts to curb the pandemic.
Gladstone Experts COVID-19 Cardiovascular Disease Srivastava Lab
POZ—Finding a cure to HIV will require a full understanding of the latent reservoir, the population of cells in which the virus hides, evading antiretroviral therapy. Gladstone scientist Nadia Roan describes her recent work mapping an atlas of the reservoir, and how it provides hope that new therapies could be developed to target and eliminate reservoir cells.
Gladstone Experts HIV/AIDS Infectious Disease Roan Lab
The New York Times—The experimental drugs used to treat President Trump for COVID-19 were developed with the help of a human cell line derived from a fetus aborted decades ago. Gladstone President Deepak Srivastava, MD, and Senior Investigator Warner Greene, MD, PhD, comment on the ethics of accepting this treatment while also banning research using newly derived fetal cells, in the process thwarting the development of life-saving treatments for other conditions.
Gladstone Experts COVID-19 Cardiovascular Disease Center for HIV Cure Research Greene Lab Srivastava Lab
San Francisco Business Times—As Scribe Therapeutics Inc., the latest company founded by Senior Investigator Jennifer Doudna, PhD, announced that it landed a deal with Biogen Inc., Gladstone President Deepak Srivastava, MD, commented on the importance of CRISPR-based biotech companies for medicine and agriculture and on Doudna’s drive as a scientist.
Gladstone Experts Cardiovascular Disease Data Science and Biotechnology Doudna Lab Srivastava Lab CRISPR/Gene Editing
San Francisco Chronicle—After the president was diagnosed with COVID-19, he received aggressive medical treatment. Gladstone Senior Investigator Warner Greene noted that the combination of drugs the president received has not been tested or proven effective, and that the dexamethasone he was given is a sign his illness might be more severe than it appears.
Gladstone Experts COVID-19 Infectious Disease Greene Lab
The Guardian—Recent work from Senior Investigators Todd McDevitt, PhD, and Bruce Conklin, MD, documenting the damaging effect of SARS-CoV-2 on heart cells is mentioned in a detailed review of the long-term impact of COVID-19 on patients’ hearts.
Gladstone Experts COVID-19 Cardiovascular Disease Data Science and Biotechnology Conklin Lab McDevitt Lab
The answer is yes. And here’s why.
Gladstone Experts COVID-19 Center for HIV Cure Research Infectious Disease Greene Lab
San Francisco Business Times—Gabaeron, founded by Gladstone President Emeritus Bob Mahley, MD, PhD, and Therini Bio (formerly Medared), founded upon work by Senior Investigator Katarina Akassoglou, PhD, are among Bay Area biotech companies focusing on neurological diseases that collectively raised more than $3 billion from venture capital firms and the public capital markets in 2020.
Gladstone Experts Parkinson’s Disease Multiple Sclerosis Alzheimer’s Disease Neurological Disease Akassoglou Lab Mahley Lab
Clinical Omics—Alex Marson, MD, PhD, director of the Gladstone-UCSF Institute of Genomic Immunology, explains his lab's recent discovery of the the gene networks that distinguish regulatory T cells from other types of T cells, and the implication for therapies against cancer and autoimmune diseases.
Gladstone Experts Autoimmune Diseases Marson Lab
Technology Network—Senior Investigator Bruce Conklin, MD, explains how SARS-CoV-2 damages heart cells and how heart cells grown in the lab could be used to screen for drugs against infection by the novel coronavirus.
Gladstone Experts COVID-19 Cardiovascular Disease Conklin Lab
Genetic Engineering and Biotechnology News—Alex Marson, MD, PhD, director of the Gladstone-UCSF Institute of Genomic Immunology, explains the implications of his lab's recent identification of gene networks that control the function of immune cells, known as regulatory T cells, for therapies against cancer and autoimmune diseases.
Gladstone Experts Autoimmune Diseases Genomic Immunology Marson Lab
